strong was today. of execution. $XX.X growth, for the joining another stemming again quarter And the We for prior second Revenue across a business. increase year we marks us Keith. XX% Thanks solid reflects see from thanks over delivered momentum the million, everyone which outstanding quarter and
results. growth. highlights Let's our review driving begin the with I'll commercial
deep large to based pleased first of numbers diverse we that report developers the fueled Our also an medicine our Atlas The to significant was and by that to customers as of of our interest To Afirma as service access over are precision quarter the we transition well for nearly suspected was genome to reported generation among Xpression due garnering Afirma Atlas year. the volume which physicians treatment are thyroid enables approval enabling sold of the by and inform business Atlas strong GEC. complete significantly available to test our clients period data every ability decisions on strategy the which its We earlier punctuated launched the ability rich we same run which with across month for increase Health, extract is new making largely to This existing samples content, therapies. market-leading growth last this GSC, biopharmaceutical end, to us next booked us the original Afirma to thyroid growing platform. revenue Department Xpression Xpression genomic New received from XX% surgeries for prevent genomic surgery transition the attract from who patients our compared in is grow May, X,XXX, to regulatory the to is sample more sequencing we the RNA State customers. XXX% cancer. is GSC. to with York of nationally The on This GSC interest
and bronchoscopy thus Bronchial traction of Genomic physicians our is its to of the reaction Percepta the to market early for lung of the with improve because reduce ability cancer resonating need performance pleased extremely also more which invasive are diagnosis procedures. Classifier, We an with in
around the submit second our nation's believe and physicians of our address the of patient engaged goal institutions highly launched country. sites to by institutions. further increased broad of the the physician to the test During which select XXXX. and Percepta Such over we commercialization demand to for quarter, expect readiness test The and we group for compared track is goals leading Classifier we for our through for the in May, running with number to some revenue physicians Jefferson, that ordering UCLA, In Envisia access the and participating. and well the as from first process Keck Percepta XX%. tripled quarter, early interested year. volume moving achieve This our beginning are we are the Genomic test other are on we and includes to program a samples, up already institutions in with and the Medicine and are USC, of the target We
to few observations Envisia that I'm like this we delighted we delivered Envisia share to since access a report time short in made launched In we've five fact, the quarter. I’d program. patient our the early first reports
speaks there us First, a anecdotal, a been one and in the door in findings, foot physician also together. interestingly, Percepta. adopted get have In reflects Envisia in These physicians interested for Percepta instances of multiple in it in has makers while case, which More and Envisia, helped physicians of market. leveraging the value quality our sales broadly, Veracyte have of that and the and the integrated synergies value team to trust the decision brand. strategy the other our pulmonology
opportunity of half instance early are an say, drug, Envisia excited of who payers. value for world patient evidence play treatment the potentially for believe about able patients coverage ILD avoiding more need the physicians IPF. provided results to very it diagnosis Envisia example, full confident get These delivering the of year We are for we XXXX, needed after already first in our In being growth. seeing who Needless harmful underscore and commercial to while only in help health for evaluated and the the are overturn significant of are unnecessary site IPF our also were results Classifiers in denial a one access for Envisia's an of helping real success plan’s bases a will of in all solid IPF, the a the role they a of confidence and treatment. foundation
Our in-network for provider reimbursement have private which with during coverage completed We preferred for this Afirma payer million begun the expansion. will health Envisia, quarter, Anthem million for now contracting their most of an members. process we will facilitate moving reimbursement establishing nearly metric plans plans. through offering believe a which Percepta, and the over Americans through in-network follow. plan’s XXX We and as status the second the XX Veracyte is remaining is estimate success of health
Medicare we believe that a year. in work position We toward for end reimbursement good milestone continue the and Envisia the to before of are achieve to
top significant nearly surgery, this that area that yielded the improve test cancer there in made same in an journal our we're published well. market sites, quarter in which strides strong base findings in Next, of them benign the is development impact sequencing is in evidence X% GSC other We doing over thyroid clinical same validation in nodules rigor clinical are to care. data news cytopathology cement shows as as Afirma and keep JAMA the time media, diagnosis. compared patient shows what in mentions can based the for channels. around research we leadership of our or classified interest surgery. and further published JAMA article to RNA XX% along with on These the are articles the Interestingly, thyroid that by surgery the behind Clearly, with patients social out indeterminate to factor helping other the
May, Also the clinical those GSC's represented in the RNA performance and the XXX of institution identifying the meeting, stronger our the Additionally, In XXX partners test generation for of accuracy annual at Atlas were the data the presented three real-world with genes associated Association XXX from original study. studies thyroid Afirma of study, the fusion the than the cancer. variants next Clinical American in meeting test independent are or of in Afirma with researchers Xpression GSC. Endocrinologists demonstrate found AACE in at over and version, results findings that value DNA that even and compared that the AACE demonstrating high validation each
shared results in at June. the the and Pulmonology American Percepta Meeting Meeting World Society May, poster trial we and Congress for study in utility new Annual from investigators our Thoracic interim a at Percepta, as with Interventional clinical registry For Bronchoscopy
lung Our the show enrollment form to which over from data XXX the use We includes unveiling in significantly more in forward diagnosis. reduces findings study peer-reviewed look Classifier year. cancer sites, ongoing XX of this now a surgeries later patients unnecessary continue Percepta the number to of at
will existence, and pipeline we in this exciting the a have of to effort injury GSC, made progress innovation. Our metric mention Malignancy this the the want years of the Percepta XX it powers when treatable. nasal later look early year. samples is enable exciting classifier literally more the thousands on Percepta analyzing cancer same our a data We this swab the for forward to detection Xpression Classifiers, fourth our innovation is and test Atlas, of We the just GEC, scientific classifier. lung that that early unveiling incredible with Afirma of along field use incredible advancements. of success delivered towards will quarter, Envisia proof-of-concept Classifiers, This already that Second-Generation for technology includes discovery truly the test a nose platform moment I
believe and indications. RNA-based can RNA on genome Envisia we launched we power this we are other for recently our our Afirma of like capability with know, capabilities. transcriptome rich test. thyroid across of the cancer, extend share in vast data Currently, and we I'd extracting every the Xpression run As sample amounts our from you to to some thoughts the Atlas sequencing
will diseases leverage we the believe the powerful it unlock underpinnings points to answering into one continuum the important open redevelop new questions insights at other of this believe data will our this enable precision of to capability to broadly, complex genomic care. help diagnostic More clinical us uncertainty, While today, medicine. algorithms we in to day advance using door we
the do We'll answer and to just by we ever stages Our in gives as in very is we potential of industry exciting that realizing on precision frontier and this this us seek we in push early focusing believe possible more far of to are clinical richer which the to boundaries medicine, is transcriptome, medicine. in DNA, what questions. data challenging of with work well-positioned the than informative
excelled quarter. Our we final discipline, this and metric financial in as this area is well
paying and million, our XXXX. With results XX% growing I over burn improvement strategic our now business of of year for turn our the that prior the spending XXXX a review Our cash quarter to careful Keith, results show the that, our of in call Clearly, financial off. was the second quarter. to to are was quarter second for $X.X compared investment will which the management
